Cardiol Therapeutics (TSX:CRDL) EV-to-EBIT : -6.05 (As of May. 16, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cardiol Therapeutics's Enterprise Value is C$180.29 Mil. Cardiol Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-29.79 Mil. Therefore, Cardiol Therapeutics's EV-to-EBIT for today is -6.05.

The historical rank and industry rank for Cardiol Therapeutics's EV-to-EBIT or its related term are showing as below:

TSX:CRDL' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.64 Med: -0.41 Max: 0.91
Current: -6.05

During the past 7 years, the highest EV-to-EBIT of Cardiol Therapeutics was 0.91. The lowest was -6.64. And the median was -0.41.

TSX:CRDL's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.59 vs TSX:CRDL: -6.05

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cardiol Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was C$37.13 Mil. Cardiol Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was C$-29.79 Mil. Cardiol Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -80.22%.

Cardiol Therapeutics EV-to-EBIT Historical Data

The historical data trend for Cardiol Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics EV-to-EBIT Chart

Cardiol Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-8.17

-3.74

-1.56

0.37

-1.25

Cardiol Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															0.37	0.18	-0.85	-1.30	-1.25

Competitive Comparison of Cardiol Therapeutics's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiol Therapeutics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's EV-to-EBIT falls into.

Cardiol Therapeutics EV-to-EBIT Calculation

Cardiol Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	180.289	/	-29.786
	=	-6.05

Cardiol Therapeutics's current Enterprise Value is C$180.29 Mil.
Cardiol Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-29.79 Mil.

Cardiol Therapeutics (TSX:CRDL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cardiol Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-29.786	/	37.13053
	=	-80.22 %

Cardiol Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was C$37.13 Mil.
Cardiol Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-29.79 Mil.

Cardiol Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiol Therapeutics (TSX:CRDL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

CRDL:USA CT9:Germany

Address

2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5

Website

https://www.cardiolrx.com

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Executives

Guillermo Torre

Senior Officer